In the last trading session, 2.17 million shares of the Sangamo Therapeutics Inc (NASDAQ:SGMO) were traded, and its beta was 1.26. Most recently the company’s share price was $0.43, and it changed around -$0.02 or -5.45% from the last close, which brings the market valuation of the company to $89.23M. SGMO currently trades at a discount to its 52-week high of $1.67, offering almost -288.37% off that amount. The share price’s 52-week low was $0.29, which indicates that the current value has risen by an impressive 32.56% since then. We note from Sangamo Therapeutics Inc’s average daily trading volume that its 3-month average coming to 2.27 million.

Sangamo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended SGMO as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Sangamo Therapeutics Inc is expected to report earnings per share of -0.15 for the current quarter.

Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information

Instantly SGMO has showed a red trend with a performance of -5.45% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -20.85% year-to-date, but still up 35.05% over the last five days. On the other hand, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -28.62% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 96.42% from its current value. Analyst projections state that SGMO is forecast to be at a low of $5 and a high of $19.

Sangamo Therapeutics Inc (SGMO) estimates and forecasts

Sangamo Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -14.82 percent over the past six months and at a 6.78% annual growth rate that is well below the industry average of 15.40%. The year-over-year growth rate is expected to be -76.70%, down from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 8.26M in revenue for the current quarter. 5 analysts expect Sangamo Therapeutics Inc to make 8.72M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 14.83M and 10.4M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -44.30%. Forecasts for the next quarter put sales growth at -16.20%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.96%.

SGMO Dividends

Sangamo Therapeutics Inc’s next quarterly earnings report is expected to be released in August.

Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 7.73% of Sangamo Therapeutics Inc shares, and 50.79% of them are in the hands of institutional investors. The stock currently has a share float of 55.05% . Sangamo Therapeutics Inc stock is held by 167 institutions, with Wasatch Advisors LP being the largest institutional investor. By Mar 31, 2024 , it held 9.70% of the shares, which is about 20.13 shares worth $8.66 million.

Armistice Capital, LLC , with 8.17% or 16.96 shares worth $7.29 million as of Mar 31, 2024 , holds the second largest percentage of outstanding shares.

Wasatch Ultra Growth Fund and Wasatch Microcap Fund were the top two Mutual Funds as of Mar 31, 2024 . The former held 11.82 shares worth $5.08 million, making up 5.69% of all outstanding shares. On the other hand, Wasatch Microcap Fund held roughly 5.32 shares worth around $2.29 million, which represents about 2.56% of the total shares outstanding.